Investing Profile

John McKearn

InvestorVC

Venture Capital / BioPharma R&D

Photo of John McKearn, Managing Director at RiverVest

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RiverVest Managing Director
$100K - $10.0M
$1M
10
$184.4M
CompanyStageDateRound SizeTotal Raised
Wugen
Series BJul 2021$172M
$172M
Co-investors: Bali Muralidhar (Abingworth)
Tioma Therapeutics
Series AAug 2016$86M
$86M
Co-investors: Peter Moldt (Novo Ventures), Jill carroll (SR One), Carole Nuechterlein (Roche Venture Fund)
Allakos
Series ASep 2014$10M
Series AAug 2014$24.5M
$134.5M
Co-investors: Paul Walker (New Enterprise Associates (NEA)), Farah Champsi (InterWest)
Otonomy
Series DApr 2014$49M
Series CSep 2013$45.9M
Series BAug 2010$38.5M
$143.4M
Co-investors: Jay Lichter (Avalon Ventures), Brian Dovey (Domain Associates), Bill Harrington (Osage University Partners), Niall O’Donnell (RiverVest), Heather Preston (Broadway Angels)
ZS Pharma
Series DMar 2014$55M
Series COct 2012$46M
$101M
Lumena Pharmaceuticals
Series AMay 2013$23M
$68M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Niall O’Donnell (RiverVest)